• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Targeting the epidermal growth factor receptor: an important incremental step in the battle against colorectal cancer.

作者信息

Ellis Lee M, Hoff Paulo M

出版信息

J Clin Oncol. 2004 Apr 1;22(7):1177-9. doi: 10.1200/JCO.2004.01.971. Epub 2004 Mar 1.

DOI:10.1200/JCO.2004.01.971
PMID:14993229
Abstract
摘要

相似文献

1
Targeting the epidermal growth factor receptor: an important incremental step in the battle against colorectal cancer.
J Clin Oncol. 2004 Apr 1;22(7):1177-9. doi: 10.1200/JCO.2004.01.971. Epub 2004 Mar 1.
2
Cetuximab.西妥昔单抗
Nat Rev Drug Discov. 2004 Jul;3(7):549-50. doi: 10.1038/nrd1445.
3
K-Ras mutations are changing practice in advanced colorectal cancer.K-Ras基因突变正在改变晚期结直肠癌的治疗实践。
J Natl Cancer Inst. 2008 Dec 3;100(23):1667-9. doi: 10.1093/jnci/djn429. Epub 2008 Nov 25.
4
Epidermal growth factor receptor as a therapeutic target in colorectal cancer.表皮生长因子受体作为结直肠癌的治疗靶点
Clin Colorectal Cancer. 2003 Feb;2(4):246-51. doi: 10.3816/CCC.2003.n.006.
5
Cetuximab for colorectal cancer.
N Engl J Med. 2008 Mar 13;358(11):1196; author reply 1196-7.
6
Cetuximab.西妥昔单抗
Nat Rev Drug Discov. 2005 May;Suppl:S10-1. doi: 10.1038/nrd1728.
7
Epidermal growth factor receptor monoclonal antibodies for the treatment of metastatic colorectal cancer.用于治疗转移性结直肠癌的表皮生长因子受体单克隆抗体
Pharmacotherapy. 2008 Jun;28(6):742-54. doi: 10.1592/phco.28.6.742.
8
Where now for anti-EGF receptor therapies in colorectal cancer?结直肠癌的抗表皮生长因子受体治疗路在何方？
Expert Rev Anticancer Ther. 2011 Oct;11(10):1543-53. doi: 10.1586/era.11.143.
9
Bevacizumab vs EGFR antibodies in metastatic colorectal cancer.贝伐单抗与表皮生长因子受体抗体治疗转移性结直肠癌的对比
Clin Adv Hematol Oncol. 2015 Feb;13(2):90-2.
10
Panitumumab following disease progression on cetuximab in patients with metastatic colorectal cancer: a retrospective review.西妥昔单抗治疗后疾病进展的转移性结直肠癌患者使用帕尼单抗的回顾性研究
J Oncol Pharm Pract. 2014 Apr;20(2):83-7. doi: 10.1177/1078155212474048. Epub 2013 Jan 24.

引用本文的文献

1
Phosphorylated AKT and MAPK expression in primary tumours and in corresponding metastases and clinical outcome in colorectal cancer patients receiving irinotecan-cetuximab.在接受伊立替康-西妥昔单抗治疗的结直肠癌患者中，原发肿瘤及其相应转移灶中磷酸化 AKT 和 MAPK 的表达与临床结局的关系。
J Transl Med. 2012 Apr 10;10:71. doi: 10.1186/1479-5876-10-71.
2
EGFR(S) inhibitors in the treatment of gastro-intestinal cancers: what's new?表皮生长因子受体（S）抑制剂在胃肠癌治疗中的应用：有哪些新进展？
Curr Drug Targets. 2010 Jun;11(6):682-98. doi: 10.2174/138945010791170851.
3
Targeting EGFR with photodynamic therapy in combination with Erbitux enhances in vivo bladder tumor response.
光动力疗法联合爱必妥靶向 EGFR 增强了膀胱癌的体内治疗反应。
Mol Cancer. 2009 Nov 2;8:94. doi: 10.1186/1476-4598-8-94.
4
A combination of gefitinib and FOLFOX-4 as first-line treatment in advanced colorectal cancer patients. A GISCAD multicentre phase II study including a biological analysis of EGFR overexpression, amplification and NF-kB activation.吉非替尼与FOLFOX - 4联合用于晚期结直肠癌患者的一线治疗。一项GISCAD多中心II期研究，包括对表皮生长因子受体（EGFR）过表达、扩增及核因子-κB（NF - kB）激活的生物学分析。
Br J Cancer. 2008 Jan 15;98(1):71-6. doi: 10.1038/sj.bjc.6604121. Epub 2007 Dec 4.
5
Epidermal growth factor receptor (EGFR) downstream signalling pathway in primary colorectal tumours and related metastatic sites: optimising EGFR-targeted treatment options.原发性结直肠癌肿瘤及相关转移部位的表皮生长因子受体（EGFR）下游信号通路：优化EGFR靶向治疗方案
Br J Cancer. 2007 Jul 2;97(1):92-7. doi: 10.1038/sj.bjc.6603847. Epub 2007 Jun 19.
6
Treatment for multiple bilobar liver metastases of colorectal cancer.结直肠癌多叶肝转移的治疗。
Langenbecks Arch Surg. 2006 Apr;391(2):130-42. doi: 10.1007/s00423-005-0003-7. Epub 2005 Dec 1.
7
Metaplastic breast carcinomas are negative for Her-2 but frequently express EGFR (Her-1): potential relevance to adjuvant treatment with EGFR tyrosine kinase inhibitors?化生性乳腺癌的Her-2呈阴性，但常表达表皮生长因子受体（EGFR，即Her-1）：这与使用EGFR酪氨酸激酶抑制剂进行辅助治疗有潜在关联吗？
J Clin Pathol. 2005 Jul;58(7):700-4. doi: 10.1136/jcp.2004.025163.
8
Clinical experience with monoclonal antibodies to epidermal growth factor receptor.针对表皮生长因子受体的单克隆抗体的临床经验。
Curr Oncol Rep. 2005 Mar;7(2):96-103. doi: 10.1007/s11912-005-0034-9.